Stonegate Capital Partners has issued an update on Burcon Nutrascience Corporation (TSX: BU), highlighting the company's transition from commissioning to early utilization at its Galesburg facility. With growing customer volume, Burcon is beginning to benefit from better fixed-cost absorption, according to the report released Thursday.
Burcon completed commissioning and launched commercial production across its Peazazz pea protein, Puratein C canola protein, and FavaPro fava protein lines during fiscal year 2026. Revenue increased sequentially to $0.83 million in the fourth quarter of 2026 from $0.74 million in the third quarter. Management indicated that current-quarter sales are tracking toward approximately 50% sequential growth based on April and May activity.
The company also set a new production record, with daily output roughly 60% above January to March levels. As volume builds, the margin opportunity should come from better utilization, a steadier production cadence, and start-up costs moving out of the run-rate cost structure, rather than pricing alone, Stonegate noted.
Customer traction is broadening, with more than 30 purchasing customers and over 200 active projects across pea, canola, and fava applications. Funding supports the Galesburg scale-up, with $6.9 million completed, $3.0 million undrawn, and management targeting $10 million of calendar year 2026 sales.
